William Blair Weighs in on Upstream Bio Q4 Earnings

Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - Equities researchers at William Blair issued their Q4 2025 earnings per share estimates for shares of Upstream Bio in a research report issued on Thursday, November 7th. William Blair analyst M. Phipps anticipates that the company will post earnings per share of ($0.66) for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Upstream Bio's current full-year earnings is ($5.75) per share.

A number of other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. initiated coverage on Upstream Bio in a report on Tuesday, November 5th. They set an "overweight" rating and a $38.00 target price on the stock. TD Cowen initiated coverage on Upstream Bio in a report on Tuesday, November 5th. They set a "buy" rating on the stock. Finally, Piper Sandler began coverage on Upstream Bio in a report on Tuesday, November 5th. They set an "overweight" rating and a $75.00 target price on the stock.

Upstream Bio Price Performance

Shares of NASDAQ UPB traded up $0.62 during midday trading on Monday, hitting $26.80. The stock had a trading volume of 220,998 shares, compared to its average volume of 324,557. Upstream Bio has a fifty-two week low of $20.74 and a fifty-two week high of $29.46.

Insiders Place Their Bets

In related news, major shareholder Ai Upstream Llc purchased 1,175,000 shares of the firm's stock in a transaction dated Tuesday, October 15th. The stock was bought at an average price of $17.00 per share, with a total value of $19,975,000.00. Following the completion of the purchase, the insider now owns 1,175,000 shares in the company, valued at approximately $19,975,000. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. In other Upstream Bio news, Director Erez Chimovits bought 825,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The shares were bought at an average price of $17.00 per share, for a total transaction of $14,025,000.00. Following the transaction, the director now directly owns 4,554,873 shares in the company, valued at approximately $77,432,841. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ai Upstream Llc bought 1,175,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $19,975,000.00. Following the transaction, the insider now owns 1,175,000 shares in the company, valued at $19,975,000. The disclosure for this purchase can be found here.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.